OA12337A - Crystalline therapeutic agent. - Google Patents

Crystalline therapeutic agent. Download PDF

Info

Publication number
OA12337A
OA12337A OA1200300008A OA1200300008A OA12337A OA 12337 A OA12337 A OA 12337A OA 1200300008 A OA1200300008 A OA 1200300008A OA 1200300008 A OA1200300008 A OA 1200300008A OA 12337 A OA12337 A OA 12337A
Authority
OA
OAPI
Prior art keywords
ethyl
compound
ethoxy
methoxyethyl
mixture
Prior art date
Application number
OA1200300008A
Other languages
English (en)
French (fr)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA12337A publication Critical patent/OA12337A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
OA1200300008A 2000-07-28 2001-07-18 Crystalline therapeutic agent. OA12337A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
OA12337A true OA12337A (en) 2006-05-15

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300008A OA12337A (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent.

Country Status (46)

Country Link
EP (1) EP1305314B1 (es)
JP (1) JP2004505087A (es)
KR (1) KR100457937B1 (es)
CN (1) CN1207297C (es)
AP (1) AP1400A (es)
AR (1) AR032628A1 (es)
AT (1) ATE286901T1 (es)
AU (2) AU2001272690B2 (es)
BG (1) BG107266A (es)
BR (1) BR0112734A (es)
CA (1) CA2417264C (es)
CZ (1) CZ2003126A3 (es)
DE (1) DE60108398T2 (es)
DO (1) DOP2001000217A (es)
DZ (1) DZ3364A1 (es)
EA (1) EA004681B1 (es)
EC (1) ECSP034454A (es)
EE (1) EE200300045A (es)
ES (1) ES2231521T3 (es)
GE (1) GEP20053494B (es)
HK (1) HK1055954A1 (es)
HR (1) HRP20030061A2 (es)
HU (1) HUP0302982A3 (es)
IL (1) IL153226A0 (es)
IN (1) IN2002MU01649A (es)
IS (1) IS6626A (es)
MA (1) MA26931A1 (es)
MX (1) MX233602B (es)
MY (1) MY117831A (es)
NO (1) NO324220B1 (es)
NZ (1) NZ523226A (es)
OA (1) OA12337A (es)
PA (1) PA8523501A1 (es)
PE (1) PE20020277A1 (es)
PH (1) PH12001001922B1 (es)
PL (1) PL365133A1 (es)
PT (1) PT1305314E (es)
SK (1) SK572003A3 (es)
SV (1) SV2001000570A (es)
TN (1) TNSN01112A1 (es)
TW (1) TWI285643B (es)
UA (1) UA72631C2 (es)
UY (1) UY26854A1 (es)
WO (1) WO2002010171A1 (es)
YU (1) YU4703A (es)
ZA (1) ZA200301457B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
GEP20084329B (en) 2003-04-29 2008-03-25 Pfizer Ltd 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
CA2562251C (en) 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
AU2006245416B2 (en) * 2005-05-12 2012-02-23 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003039T2 (tr) * 1998-04-20 2001-01-22 Pfizer Inc. Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
NZ523226A (en) 2003-07-25
TWI285643B (en) 2007-08-21
WO2002010171A1 (en) 2002-02-07
EP1305314B1 (en) 2005-01-12
DE60108398D1 (de) 2005-02-17
BR0112734A (pt) 2004-08-10
HUP0302982A3 (en) 2005-01-28
PT1305314E (pt) 2005-04-29
PH12001001922B1 (en) 2006-11-21
JP2004505087A (ja) 2004-02-19
UA72631C2 (uk) 2005-03-15
CN1207297C (zh) 2005-06-22
PA8523501A1 (es) 2002-10-24
NO324220B1 (no) 2007-09-10
HRP20030061A2 (en) 2003-04-30
TNSN01112A1 (fr) 2005-11-10
AU2001272690B2 (en) 2005-12-08
EE200300045A (et) 2004-12-15
CZ2003126A3 (cs) 2004-02-18
CA2417264A1 (en) 2002-02-07
EA004681B1 (ru) 2004-06-24
SK572003A3 (en) 2004-05-04
ECSP034454A (es) 2003-03-10
NO20030416D0 (no) 2003-01-27
ATE286901T1 (de) 2005-01-15
EA200300079A1 (ru) 2003-06-26
DE60108398T2 (de) 2005-12-22
DZ3364A1 (fr) 2002-02-07
MY117831A (en) 2004-08-30
BG107266A (bg) 2003-07-31
SV2001000570A (es) 2002-09-03
UY26854A1 (es) 2002-02-28
ES2231521T3 (es) 2005-05-16
PL365133A1 (en) 2004-12-27
AP1400A (en) 2005-04-28
MX233602B (es) 2006-01-10
AP2001002234A0 (en) 2001-09-30
AU7269001A (en) 2002-02-13
AR032628A1 (es) 2003-11-19
KR100457937B1 (ko) 2004-11-20
HK1055954A1 (en) 2004-01-30
MA26931A1 (fr) 2004-12-20
HUP0302982A2 (hu) 2003-12-29
KR20030016430A (ko) 2003-02-26
MXPA03000856A (es) 2003-06-06
IL153226A0 (en) 2003-07-06
YU4703A (sh) 2006-01-16
EP1305314A1 (en) 2003-05-02
NO20030416L (no) 2003-02-05
IN2002MU01649A (es) 2004-12-11
PE20020277A1 (es) 2002-05-11
DOP2001000217A (es) 2002-10-30
CN1444585A (zh) 2003-09-24
ZA200301457B (en) 2004-04-28
IS6626A (is) 2002-11-18
CA2417264C (en) 2007-06-12
GEP20053494B (en) 2005-04-25

Similar Documents

Publication Publication Date Title
CN100378100C (zh) 吡唑并[4,3-d]嘧啶衍生物
EP1372656B1 (en) Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors
NZ566087A (en) Novel crystalline form of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4, 5-b]indole-1-acetamide
US20010049439A1 (en) Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same
OA12337A (en) Crystalline therapeutic agent.
US6420557B1 (en) Crystalline therapeutic agent
AU2001272690A1 (en) Crystalline therapeutic agent
US6350751B1 (en) Therapeutic agents
EP1220855B1 (en) Anhydrous salt
CN113226321A (zh) 吡唑基化合物及其使用方法
JP2003128653A (ja) 結晶性物質